Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions

Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions

John A D’Elia,1 Alissa R Segal,1,2 George P Bayliss,3 Larry A Weinrauch1 1Kidney and Hypertension Section, Joslin Diabetes Center, Harvard Medical School, 2Department of Pharmacy Practice, MCPHS University, Boston, MA, 3Division of Kidney Diseases and Hypertension, Rhode Island Hospital, A...

Full description

Bibliographic Details
Main Authors: D'Elia JA, Segal AR, Bayliss GP, Weinrauch LA
Format: Article
Language:English
Published: Dove Medical Press 2017-06-01
Series:International Journal of Nephrology and Renovascular Disease
Subjects:
SGLT2 inhibitor
diabetes
ketoacidosis
FDA
Online Access:https://www.dovepress.com/sodium-glucose-cotransporter-2-inhibition-and-acidosis-in-patients-wit-peer-reviewed-article-IJNRD

Internet

https://www.dovepress.com/sodium-glucose-cotransporter-2-inhibition-and-acidosis-in-patients-wit-peer-reviewed-article-IJNRD

Similar Items